Companies Sign Manufacturing Agreements Aimed at Increasing Biosimilar Access, Affordability
March 16th 2022OcyonBio signed a Good Manufacturing Practice (GMP) agreement for the manufacturing of biosimilars in Puerto Rico, while Evio Pharmacy Solutions implemented a strategy aimed at increasing biosimilar affordability.
Celltrion Biosimilar Demonstrates Equivalence With Xolair in Phase 1 Study
March 14th 2022A phase 1 study testing Celltrion Healthcare’s omalizumab biosimilar in healthy subjects showed similar safety and pharmacokinetic profiles to the reference product (Xolair), as presented at the American Academy of Allergy Asthma and Immunology’s annual meeting.
AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
March 8th 2022AbbVie settles outstanding lawsuits, including its case related to the International Trade Commission (ITC), with Alvotech, giving Alvotech the green light to launch its high-concentration, citrate-free adalimumab biosimilar referencing Humira in July 2023, pending FDA approval.
What Employers Can Do to Stand Up for Biosimilar Formulary Placement
February 24th 2022A report from the National Alliance of Healthcare Purchaser Coalitions detailed the common concerns employers have regarding implementing biosimilars within their health care plans and outlined how they could take charge and make a difference.
Experts Call for More Regulatory Action to Address Biosimilar Interchangeability Confusion
February 17th 2022A panel of experts details the current concerns regarding interchangeability designations for biosimilars in the United States and calls for regulators and policy makers to make changes to allow to easier access to biosimilars and greater adoption.
The Biosimilars Forum's Julie Reed Shares Her Major Goals for the Organization in New Role
February 13th 2022Improving access and getting big legislative changes for biosimilars passed are just some of the many plans that Julie M. Reed, the new executive director of the Biosimilars Forum, has for the organization.
Biogen, Xbrane Enter Commercialization Agreement for Cimzia Biosimilar
February 10th 2022Biogen and Xbrane Biopharma signed a commercialization agreement for Xcimzane, a certolizumab pegol biosimilar referencing Cimzia for the treatment of rheumatoid arthritis, psoriasis, and other rheumatologic conditions.